Mentioned is our project Apollo a first of its kind 100-patient clinical trial – using an unbiased, CLIA (Clinical Laboratory Improvement Amendment) certified high-throughput test (P.A.R.I.S®, SEngine Precision Medicine) to identify specific sensitivities in each patient from a large panel of oncology drugs.
Goldie Lui et. al. look at the CDK12 gene as an emerging therapeutic target for cancer. Click here to read the article in the Journal of Clincal Pathology 2018
The partnership and technologies developed by Cure First, SEngine Precision Medicine, in collaboration with Englander Institute for Precision Medicine at Weill Cornell Medicine, led to a seminal study in prostate cancer. Personalized cancer models from patients were developed and novel therapeutic combinations discovered and validated.
See the Fred Hutch Science Spotlight about the published Clinical Cancer Research paper.
Seattle Startup Takes Precision Oncology to the Next Step: Carla Grandori, CEO, SEngine
Academic Industrial Partnership for Translation of Technologies for Cancer Diagnosis and Treatment
Cure First, a non-profit research organization, and SEngine Precision Medicine co-authored one of 27 high-profile papers published today by Cell Press.
SEngine partners with Knight Cancer Institute at OHSU and Fred Hutch researchers to bring personalized, cancer-fighting tech to patients.
SEngine team presenting five posters at American Association for Cancer Research annual conference.
Got f(x)? Join The Society for Functional Precision Medicine (SFPM) and help advance the science and medicine of direct functional testing of patient cancer cells. SFPM's mission is to facilitate implementation of functional assays into clinical care.
CELL Press released 27 papers which are part of the PanCancer Atlas. SEngine in-depth analysis of the MYC oncogene across 11,000 samples and 33 tumor types published in Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.
It's official. Research by Cure First and SEngine Precision Medicine scientists including CEO and Founder Carla Grandori, MD. Ph.D. and Principal Scientist Franz Schaub identifying a common gene in nearly 30% of all cancers just published in Cell Press.
Incredible speakers tackle key challenges. The Seattle conference tackles the future of functional precision oncology.
An important read about the foundation and future of functional precision medicine to help current cancer patients and the oncologists who treat them. As told by SEngine Precision Medicine CEO Carla Grandori, MD. Ph.D.
Personalized Oncology Screening Results Validated in Method Developed by Seattle Cancer Research Organizations. Click here to read the paper in Cancer Discovery (PMID_28331002).
Want Access To Our Posters from Our Scientific Presentation at AACR 2018?
To download please fill out the form below.